Neurogene filed to sell shares in a public offering.

The clinical-stage biotechnology company didn't specify how many shares it plans to sell or at what price, according to a filing with the Securities and Exchange Commission on Tuesday. Some investors may receive pre-funded warrants instead of common stock, and underwriters are expected to have a 30-day option to buy additional shares.

Shares declined 4.6% to $30 in post-market trading following disclosure of the company's plan. The stock was off by 2.6% to close the regular trading session at $31.45. Through the close the stock is up 53% this year.

Neurogene said it intends to use proceeds from the sale to fund clinical development and pre-commercial activities for NGN-401, working capital and other general corporate purposes.

NGN-401 is an investigational gene therapy being developed for use as a one-time treatment for Rett syndrome, a rare genetic neurodevelopmental disorder that affects 1 put of every 10,000 live female births in the world.

The company earlier this year reported a first-quarter loss of $30.9 million, or $1.39 per share, compared with a loss of $22.6 million, or $1.08 per share, a year earlier.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

June 30, 2026 16:52 ET (20:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.